Hyaluronidase-triggered anticancer drug and siRNA delivery from cascaded targeting nanoparticles for drug-resistant breast cancer therapy

Ding, Jie; Liang, Tingxizi; Zhou, Ying; He, Zhiwei; Min, Qianhao; Jiang, Liping; Zhu, Jun‐Jie

doi:10.1007/s12274-016-1328-y

Cited by 50 publications

(32 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Taken together, HA‐based NPs can be utilized for diseases including various kinds of cancer, RA, and diabetes, as carriers for chemotherapy (CHT), photodynamic therapy, and photothermal therapy, along with carriers for biologics such as siRNA and applications in immunotherapy (IMT) ( Table 3 ). In the end, these examples demonstrate the diverse possibilities available by using HA‐based NPs as actively targeted carriers and/or triggered delivery systems in response to Hyal overexpression at localized sites of disease.…”

Section: Stimuli‐responsive Nanomaterials Based On Hyaluronic Acidmentioning

confidence: 99%

Hyaluronic Acid–Based Activatable Nanomaterials for Stimuli‐Responsive Imaging and Therapeutics: Beyond CD44‐Mediated Drug Delivery

et al. 2019

View full text Add to dashboard Cite

There is a rapidly increasing interest in developing stimuli-responsive nanomaterials for treating a variety of diseases. By enabling the activation of function locally at the sites of interest, it is possible to increase therapeutic efficacy significantly while simultaneously reducing adverse side effects. While there are many sophisticated nanomaterials available, they are often highly complex and not easily transferrable to industrial scales and clinical settings. However, nanomaterials based on hyaluronic acid offer a compelling strategy for reducing their complexity while retaining several desirable benefits such as active targeting and stimuli-responsive degradation. Herein, the basic properties of hyaluronic acid, its binding partners, and natural routes for degradation by hyaluronidases-hyaluronic-aciddegrading enzymes-and oxidative stresses are discussed. Recent advances in designing hyaluronic acid-based, actively targeted, hyaluronidase-or reactive-oxygen-species-responsive nanomaterials for both diagnostic imaging and therapeutic delivery, which go beyond merely the classical targeting of CD44, are summarized.

show abstract

Section: Stimuli‐responsive Nanomaterials Based On Hyaluronic Acidmentioning

confidence: 99%

Hyaluronic Acid–Based Activatable Nanomaterials for Stimuli‐Responsive Imaging and Therapeutics: Beyond CD44‐Mediated Drug Delivery

et al. 2019

View full text Add to dashboard Cite

show abstract

“…HA can be 25,000 disaccharide repeats in length inhibits lymphoid tissue invasion in a murine model developed for Tcell lymphoma. Mice have many alleles for hyal1; however, there is only one allele present for Hyal1 in humans (Ding et al, 2017, Shuster, Frost, Csoka, Formby, & Stern, 2002. Murine alleles have completely various levels of enzyme activity.…”

Section: Anticancer Properties Of Hyalmentioning

confidence: 99%

Purification of hyaluronidase as an anticancer agent inhibiting CD44

Shakouri

Adljouy

Abdolalizadeh

2019

Biomedical Chromatography

View full text Add to dashboard Cite

Hyaluronidase (Hyal) can be employed to accomplish a diversity of complications related to hyaluronic acid (HA). Hyal contains some classes of catalysts that cleave HA. This enzyme is detected in several human tissues as well as in animal venoms, pathogenic organisms and cancers. Destructive cancer cells regularly increase the CD44 receptor existing in a cell membrane. This receptor acts as an exact receptor for HA, and HA is recognized to motivate the migration, spread, attack and metastasis of cancer cells. Nearly all of the methods used to purify Hyal are highly costly and not proper for industrial applications. This survey aims to review different methods of Hyal purification, which acts as an anticancer agent by degrading HA in tissues and thus inhibiting the CD44–HA interaction. Hyal can be successfully employed in the management of cancer, which is associated with HA–CD44. This review has described different methods for Hyal purification to prepare an origin to develop a novel purification technique for this highly appreciated protein. Using multiple columns is not applicable for the purification of Hyal and thus cannot be used at the industrial level. It is better to use affinity chromatography of anti‐Hyal for Hyal with one‐step purification.

show abstract

“…Additionally, significantly over-expressed CD44 receptors form the hallmark of various breast cancer subtypes, including TNBC. To achieve tumour-specific targetability, reduced drug resistance and improve anticancer efficacy, several HA-conjugated or -decorated nanocarrier systems, such as nanoassemblies [30], SLNs [31], NPs [32], graphene oxide (GO) NPs [33], poly-lactide-co-glycolide (PLGA)-NPs [34], micelles [35,36] and NLCs [37] have been fabricated for treatment of breast cancer.…”

Section: Treatment Of Breast Cancer: Ha-conjugated Multifunctional Namentioning

confidence: 99%

“…Consequently, for the inhibition of cIAP1 and Bcl-xL, small interference RNA (siRNA) holds great promise for down-regulation of CTGF and consequent prevention of the associated drug resistance. In an attempt to alleviate the development of MDR, improving target-specific delivery of anticancer agents, and enhancing anticancer efficacy, mesoporous silica NPs were constructed coupled with breast cancer navigating and cell penetrating peptide (PEGA-pVEC) and HA [32]. These NPs were simultaneously loaded with siRNA and DOX and targeted against MBA-MD 231 cells.…”

Section: Treatment Of Breast Cancer: Ha-conjugated Multifunctional Namentioning

confidence: 99%

“…These NPs were simultaneously loaded with siRNA and DOX and targeted against MBA-MD 231 cells. Results indicated that upon successfully penetrating the target cancer cells via dual activity of the penetrating peptide and HA, siRNA was able to silence the anti-apoptotic proteins further allowing DOX to execute its anticancer effect [32].…”

Section: Treatment Of Breast Cancer: Ha-conjugated Multifunctional Namentioning

confidence: 99%

See 1 more Smart Citation

New developments and clinical transition of hyaluronic acid-based nanotherapeutics for treatment of cancer: reversing multidrug resistance, tumour-specific targetability and improved anticancer efficacy

Safdar

Hussain

Abourehab

et al. 2017

Artificial Cells, Nanomedicine, and Biotechnology

View full text Add to dashboard Cite

This review aims to overview and critically analyses recent developments in achieving tumour-specific delivery of anticancer agents, maximizing anticancer efficacy, and mitigating tumour progression and off-target effects. Stemming from critical needs to develop target-specific delivery vehicles in cancer therapy, various hyaluronic acid (HA)-conjugated nanomedicines have been fabricated owing to their biocompatibility, safety, tumour-specific targetability of drugs and genes, and proficient interaction with cluster-determinant-44 (CD44) receptors over-expressed on the surface of tumour cells. HA-based conjugation or surface modulation of anticancer drugs encapsulated nanocarriers have shown promising efficacy against the various types of carcinomas of liver, breast, colorectal, pancreatic, lung, skin, ovarian, cervical, head and neck and gastric. The success of this emerging platform is assessed in achieving the rapid internalization of anticancer payloads into the tumour cells, impeding cancer cells division and proliferation, induction of cancer-specific apoptosis and prevention of metastasis (tumour progression). This review extends detailed insight into the engineering of HA-based nanomedicines, characterization, utilization for the diagnosis or treatment of CD44 over-expressing cancer subtypes and emphasizing the transition of nanomedicines to clinical cancer therapy.

show abstract

Hyaluronidase-triggered anticancer drug and siRNA delivery from cascaded targeting nanoparticles for drug-resistant breast cancer therapy

Cited by 50 publications

References 31 publications

Hyaluronic Acid–Based Activatable Nanomaterials for Stimuli‐Responsive Imaging and Therapeutics: Beyond CD44‐Mediated Drug Delivery

Hyaluronic Acid–Based Activatable Nanomaterials for Stimuli‐Responsive Imaging and Therapeutics: Beyond CD44‐Mediated Drug Delivery

Purification of hyaluronidase as an anticancer agent inhibiting CD44

New developments and clinical transition of hyaluronic acid-based nanotherapeutics for treatment of cancer: reversing multidrug resistance, tumour-specific targetability and improved anticancer efficacy

Contact Info

Product

Resources

About